Famciclovir Tablets (Famciclovir)

Adult dose

Treatment of herpes zoster: Adults: Administer 250 mg of famciclovir orally 3 times daily for 7 days. It is advisable to start treatment as soon as symptoms appear after infection. Treatment of initial genital herpes infection: Adults: Administer 250 mg of this medicine orally 3 times daily for 5 days. It is advisable to start treatment as soon as symptoms appear after infection. Treatment of acute recurrent genital herpes infection: Adults: Administer 125 mg of this medicine orally 2 times daily for 5 days. It is advisable to start treatment during the prodromal period or as soon as symptoms appear after infection. Suppression of recurrent genital herpes: Adults: Administer 250 mg of this medicine orally 2 times daily. Discontinue treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. Patients with renal impairment: Because creatinine clearance of this medicine is reduced in patients with renal impairment, dosage adjustment should be undertaken with caution. The dosage and administration for these patients are as follows. Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose 2 times daily Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 10～29: 250 mg per dose once daily Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg per dose 2 times daily Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 10～29: 125 mg per dose once daily Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose 2 times daily Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 10～29: 125 mg per dose 2 times daily If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Male: {weight(kg) × (140-age)}/ {72 × serum creatinine(mg/dL)} Female: 0.85 × the value calculated for males Patients with renal impairment undergoing hemodialysis: It is advisable to administer this medicine every 48 hours, taking the dialysis interval into account. Hemodialysis for 4 hours reduces the plasma concentration of this medicine by approximately 75%; therefore, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. Patients with hepatic impairment: No dosage adjustment is necessary for patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, no clear recommended dose has been established.

This medication should not be used in patients with a known allergy to this drug or any of its components, particularly the active ingredient, penciclovir. It contains lactose, therefore it should not be administered to patients with hereditary issues such as lactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Patients with impaired kidney function need to exercise caution while using this medication, and dosage adjustments may be necessary. During treatment, symptoms such as headache, dizziness, nausea, vomiting, abdominal pain, and diarrhea may occur; if symptoms are severe, consult a physician. Additionally, skin rashes or itching, and rarely, severe skin reactions may occur; any unusual symptoms should be reported to healthcare professionals immediately. This medication does not cure genital herpes, and there remains a risk of transmission during treatment, so it is important to maintain safe sexual practices. If dizziness, drowsiness, or confusion occurs while taking this medication, it is advisable to avoid driving or operating machinery. Patients with mild hepatic impairment generally do not require special dosage adjustments, but those with severe liver impairment should be cautious as drug efficacy may be reduced. There is a low potential for interactions with other medications, but caution is advised when used with drugs that are excreted by the kidneys, such as probenecid, as blood concentration may increase. Women who are pregnant or may become pregnant should use this medication only when the benefits outweigh the risks; similarly, breastfeeding women should use it with caution. The safety and efficacy of this medication have not been established in children under 18 years old, so its use is not recommended. Elderly patients typically do not need dosage adjustments; however, adjustments should be made in cases of reduced kidney function. In case of overdose, appropriate treatment and possibly hemodialysis may be used to lower drug concentration. Finally, this medication should be stored in a sealed container to protect it from air and moisture, and it should be kept in a cool, dry place below 30 degrees Celsius, out of reach of children, and not transferred to another container.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is also recommended to store it in a cool, dry place below 30 degrees Celsius.

Appearance

White, round, film-coated tablet

Package unit

21 tablets/box [7 tablets/PTP×3]